Dipeptidyl peptidase-I inhibitors and uses thereof
US5602102A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 29, 1992 |
| Grant date | Feb 11, 1997 |
| Priority date | — |
| Expiry date | May 29, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/33
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Therapeutic agents and methods for the treatment of immunologically mediated diseases and malignancies of myeloid cell or lymphoid cell origin. These particular methods utilize the characterization of particular activation mechanisms important to the progression of these pathologies in humans. Selective inhibition of cell types responsible for precipitating these disorders in humans are provided with therapeutic agents which include peptides capable of inhibiting dipeptidyl peptidase-I activation of proenzymes present primarily in cytotoxic T-cells and myeloid cells, such as Gly--Phe--CHN.sub.2. Antisense oligonucleotides are also characterized which are specific for human dipeptidyl peptidase-I gene which may be used in the treatment of the described disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.